The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).
 
Sudpreeda Chainitikun
No Relationships to Disclose
 
James Long
No Relationships to Disclose
 
Ruben Rodriguez-Bautista
No Relationships to Disclose
 
Toshiaki Iwase
No Relationships to Disclose
 
Debu Tripathy
Consulting or Advisory Role - Genomic Health; GlaxoSmithKline; Nektar; Novartis; Pfizer; Polyphor; Sellas Life Sciences
Research Funding - Novartis (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - Novartis
 
Takeo Fujii
No Relationships to Disclose
 
Naoto T. Ueno
Honoraria - Amgen; Chugai/Roche; Eisai; Henry Stewart Talks; Kyowa Hakko Kirin; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Immunomedics; Samsung Bioepis
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Puma Biotechnology; Sysmex
Travel, Accommodations, Expenses - Kyowa Hakko Kirin